Linguistic Validation of the Turkish Version of the M.D. Anderson Symptom Inventory - Head and Neck Cancer Module

Abstract

Background: The use of patient symptom reports with frequent symptom assessment may be preferred over the more commonly used health-related quality of life questionnaires. Aims: We sought to linguistically validate the Turkish version of the M.D. Anderson Symptom Inventory-Head and Neck module (MDASI-HN) patient reported outcome questionnaire. Study Design: Validation study. Methods: Following standard forward and backward translation of the original and previously validated English MDASI-HN into a Turkish version (T-MDASI-HN), it was administered to patients with head and neck cancer able to read and understand Turkish. Patients were then cognitively debriefed to evaluate their understanding and comprehension of the T-MDASI-HN. Individual and group responses are presented using descriptive statistics. Results: Twenty-six participants with head and neck cancer completed the T-MDASIHN and accompanying cognitive debriefing. Overall, 97 percent of the individual TMDASI-HN items were completed. Average recorded time to complete the 28 item TMDASI-HN questionnaire was 5.4 minutes (range 2-10). Average overall ease of completion, understandability, and acceptability were favorably rated at 1.0, 1.1, and 0.2, respectively, on scales from 0 to 10. Only 5 of the 26 of participants reported trouble completing any single questionnaire items, namely the “difficulty remembering” item for 3 individuals. Conclusion: The T-MDASI-HN is linguistically valid with ease of completion, relevance, comprehensibility, and applicability and it can be a useful clinical and research tool.

Keywords

• Head and neck cancer, patient-reported questionnaire, patient symptoms, Turkish MDASI-HN

References

1. 1. Rosenthal DI, Mendoza TR, Fuller CD, Hutcheson KA, Wang XS, Hanna EY, et al. Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. Cancer 2014;120:1975-84. [CrossRef]
2. 2. Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 2012;30:4249-55. [CrossRef]
3. 3. Cleeland CS, Sloan JA. Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards. J Pain Symptom Manage 2010;39:1077-85. [CrossRef]
4. 4. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrisey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000;89:1634-46. [CrossRef]
5. 5. Ivanova MO, Ionova TI, Kalyadina SA, Uspenskaya OS, Kishtovich AV, Guo H, et al. Cancer-related symptom assessment in Russia: validation and utility of the Russian M. D. Anderson Symptom Inventory. J Pain Symptom Manage 2005;30:443-53. [CrossRef]
6. 6. Lin C-C, Chang A-P, Cleeland CS, Mendoza TR, Wang XS. Taiwanese version of the M. D. Anderson symptom inventory: symptom assessment in cancer patients. J Pain Symptom Manage 2007;33:180-8. [CrossRef]
7. 7. Mystakidou K, Cleeland C, Tsilika E, Katsouda E, Primikiri A, Parpa E, et al. Greek M.D. Anderson Symptom Inventory: validation and utility in cancer patients. Oncology 2004;67:203-10. [CrossRef]
8. 8. Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, et al. Japanese version of the MD Anderson Symptom Inventory: a validation study. J Pain Symptom Manage 2003;26:1093-104. [CrossRef]

9. 9. Wang XS, Wang Y, Guo H, Mendoza Tr, Hao XS, Cleeland CS. Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Cancer 2004;101:1890-901. [CrossRef]
10. 10. Yun YH, Mendoza TR, Kang IO, You CH, Roh JW, Lee CG, et al. Validation study of the Korean version of the M. D. Anderson Symptom Inventory. J Pain Symptom Manage 2006;31:345-52. [CrossRef]
11. 11. Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, et al. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck 2007;29:923-31. [CrossRef]
12. 12. Rosenthal DI, Mendoza TR, Chambers MS, Burkett VS, Garden AS, Hessell AC, et al. The M. D. Anderson symptom inventoryhead and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. Int J Radiat Oncol Biol Phys 2008;72:1355-61. [CrossRef]
13. 13. Gunn GB, Mendoza TR, Fuller CD, Gning I, Frank SJ, Beadle BM, et al. High symptom burden prior to radiation therapy for head and neck cancer: a patient-reported outcomes study. Head Neck 2013;35:1490-8.
14. 14. Shi Q, Mendoza TR, Gunn GB, Wang XS, Rosenthal DI, Cleeland CS. Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Qual Life Res 2013;22:2331-9. [CrossRef]
15. 15. Sheu T, Fuller CD, Mendoza TR, Garden AS, Morrison WH, Beadle BM et al. Nomogram for Predicting Symptom Severity during Radiation Therapy for Head and Neck Cancer. Otolaryngol Head Neck Surg 2014;151:619-26. [CrossRef]
16. 16. Gunn GB, Koukourakis MI, Mendoza TR, Cleeland CS, Rosenthal DI. Linguistic validation of the Greek M.D. Anderson Symptom Inventory - Head and Neck Module. Forum Clin Oncol 2012;3:29-31.
17. 17. Wild D, Grove A, Martin M, Eremenco S, McElroy S, VerjeeLorenz A, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005;8:94-104. [CrossRef]
18. 18. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006;4:79. [CrossRef]
19. 19. Karabulut N, Erci B, Ozer N, Ozdemir S. Symptom clusters and experiences of patients with cancer. J Adv Nurs 2010;66:1011-21.[CrossRef]